Please login to the form below

Not currently logged in

China’s BrightGene successfully copies Gilead’s coronavirus hopeful remdesivir

Raises concerns over patent exclusivity in the country


UPDATED 5 MARCH 2020: BrightGene has since been censured by the Shanghai Stock Exchange (SSE) for making misleading claims and disclosing inaccurate information over its alleged manufacture of remdesivir.

In a statement, the SSE said that BrightGene has not gained approval from China's drug regulator to manufacture the drug, and neither has it gained a licence from the patent owner Gilead to manufacture the drug on a large scale.

BrightGene has only been able to make small quantities of the drug, rather than the enough for commercial sale, which it had originally claimed.

ORIGINAL ARTICLE 13 FEBRUARY 2020: Chinese pharma BrightGene has reported that it has successfully copied remdesivir, an experimental therapy which has shown promise against the novel coronavirus.

However, Gilead which holds all patents around the development and production of the drug – including for its development as a treatment for coronavirus.

The novel coronavirus – recently named COVID-19 by the World Health Organization – has claimed 1,350 lives so far, with the majority of cases occurring in China, the epicentre of the outbreak.

The country has reported almost 60,000 cases of the infection, which has spread to a number of countries – including the UK, which has reported a total of nine confirmed cases.

In an attempt to stop the spread of the disease, researchers as well as Chinese health authorities have been testing a number of experimental therapies against COVID-19.

The one with the most potential – so far – has been antiviral drug remdesivir, which Gilead had already been developing as a treatment for Ebola disease and Marbug virus infections.

Although BrightGene has said it has successfully developed and manufactured copies of the drug, it has also maintained that it will not launch the drug until it has received licensing from Gilead, conducted clinical trials and obtained approval.

A study of remdesivir in COVID-19 has already begun enrolling patients in China, with a Gilead spokesman confirming that two clinical trials will be conducted in Wuhan, the city where the first cases of the novel coronavirus were observed.

A Chinese state-owned news agency – Xinhua – has reported that trials have already officially launched, following the approval by China’s National Medical Products Administration of applications by the China-Japan Friendship Hospital, as well as the Chinese Academy of Medical Sciences, to conduct the trials.

The Friendship Hospital will study 761 patients with COVID-19 in two trials – one to assess those with mild-to-moderate cases of the virus and another to assess severely affected patients in Wuhan.

The news reflects a larger issue of patent exclusivity in China, and in particular, around remdesivir. Researchers at the Wuhan Institute of Virology have already filed an application in China to patent remdesivir, although Gilead has indicated that it already holds a patent for the drug in China.

Following its announcement, BrightGene saw its share climb 20%, increasing to RMB 52.12 ($7.48) per share.

Article by
Lucy Parsons

13th February 2020

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

Women in science
The role of women in science and technology
Why the lack of female leaders in pharma and life sciences is a problem that still needs to be fixed...
Maria Dahl
China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances
China secures a place at the forefront of innovative medicine...
Virtual Research Grants Submission and Approval Program
Impetus Digital summarizes how a client established an independent grant review committee and a virtual grant submission and approval program, without having to travel and meet in person....